F10 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Rivaroxaban (SCHEMBL3914)	1.00	20/20
SCHEMBL49000	1.00	20/20
Otamixaban (SCHEMBL52983)	1.00	20/20
Eribaxaban (SCHEMBL76436)	1.00	20/20
SCHEMBL76791	1.00	20/20
SCHEMBL76957	1.00	20/20
SCHEMBL76970	1.00	20/20
SCHEMBL77072	1.00	20/20
SCHEMBL77189	1.00	20/20
SCHEMBL77202	1.00	20/20
SCHEMBL77206	1.00	20/20
SCHEMBL77367	1.00	20/20
SCHEMBL77413	1.00	20/20
SCHEMBL77424	1.00	20/20
SCHEMBL77551	1.00	20/20
SCHEMBL77589	1.00	20/20
Rivaroxaban (SCHEMBL77766)	1.00	20/20
SCHEMBL77930	1.00	20/20
SCHEMBL78024	1.00	20/20
SCHEMBL78027	1.00	20/20

Clinical trials — most relevant to F10 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Impact of Two Guided Transfusion Strategies on Blood Product Requirements in Liver Transplantation.	PHASE4	UNKNOWN
Enhancement of the Haemostatic Effect of Platelets in the Presence of High Normal Concentrations of Von Willebrand Factor	PHASE4	RECRUITING
Treatment With Aspirin Alone Versus Aspirin in Combination With Fondaparinux Before Early Coronary Assessment in Patients With Non-ST-Elevation Myocardial Infarction	PHASE4	RECRUITING
PCC Treatment for Hemophilia Patients With Inhibitor（2022PCC-A）	PHASE4	RECRUITING
A Study to Investigate Bio Product Laboratory Ltd (BPL's) Factor X in the Prophylaxis of Bleeding in Children <12 Years	PHASE3	COMPLETED
Study of Recombinant Factor IX Product, IB1001, in Previously Treated Subjects With Hemophilia B	PHASE3	WITHDRAWN
A Study Investigating Treatment Factor X in People With Factor X Deficiency	PHASE3	COMPLETED
A Safety, Efficacy and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Children With Hemophilia B	PHASE3	COMPLETED
An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.	PHASE3	COMPLETED
Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Chinese Subjects With Hemophilia B Previously Treated With FIX Therapy	PHASE3	ACTIVE_NOT_RECRUITING
Fiix-prothrombin Time for Monitoring Warfarin	PHASE2	COMPLETED
Safety and Efficacy of TAK-442 in Subjects With Acute Coronary Syndromes	PHASE2	COMPLETED
Study of Next-Generation Recombinant Factor IX Variant in Adult Subjects With Hemophilia B	PHASE2	COMPLETED
Effects of TNX-832 (Sunol cH36) in Subjects With Acute Lung Injury/Acute Respiratory Distress Syndrome	PHASE1	COMPLETED
Safety and Dosing Evaluation of REG1 Anticoagulation System	PHASE1	COMPLETED
A Two-part Study in Edoxaban-treated Healthy Subjects to Establish a Punch Biopsy Bleeding Model and to Evaluate the Effect of a 4-factor Prothrombin Complex Concentrate on Anticoagulation	PHASE1	COMPLETED
TP10 Use in Patients With C3 Glomerulopathy (C3G)	PHASE1	WITHDRAWN
Risk Factors of Venous Thromboembolism in Women During Hormonal Exposure	nan	RECRUITING
Correlation Between PT and INR to Factor 7	nan	UNKNOWN
Thrombophilic Risk Factors in Preterm and Infants Treated at Ha'Emek Medical Center Between the Years 1990 to 2010	nan	UNKNOWN
Coagulation After Intravenous Methylprednisolone Administration	nan	COMPLETED
Liver Biopsy In Haemophilia Gene Therapy	nan	RECRUITING
Heparin Management During Cardiopulmonary Bypass in Children	nan	COMPLETED
Platelet Function in Minimal Extracorporeal Circulation in CABG	nan	COMPLETED
Genetic Influence of Genetic Factors Influencing the Desmopressin's Efficacy in Mild/Moderate Hemophilia A	nan	UNKNOWN
Intra-graft Coagulation Events in Clinical Renal Transplantation and Delayed Graft Function	nan	UNKNOWN
Risk Factors of Neonatal Thrombosis	nan	COMPLETED
Effect of Bevacizumab and VEGF on Platelet Clustering in Patients Who Are Receiving Bevacizumab for Cancer	nan	UNKNOWN
Protein S and Myocardial Infarction	nan	COMPLETED
The Change of Coagulation Markers in Children With β-thalassemia Disease After Stem Cell Transplantation	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a F10 binder may also engage these)

Protein	Name	Similarity
O88947	—	1.000	O88947 →
Q63207	—	1.000	Q63207 →
P00743	—	1.000	P00743 →
P31394	—	1.000	P31394 →
Q58L93	—	1.000	Q58L93 →
P33587	—	0.999	P33587 →
Q804X6	—	0.999	Q804X6 →
O19045	—	0.998	O19045 →
A6MFK7	—	0.998	A6MFK7 →
Q5R537	—	0.998	Q5R537 →
P49150	—	0.997	P49150 →
Q1L658	—	0.997	Q1L658 →
Q9GLP2	—	0.997	Q9GLP2 →
P19221	—	0.997	P19221 →
Q95ND7	—	0.997	Q95ND7 →
Q58L94	—	0.996	Q58L94 →
P00741	—	0.996	P00741 →
P00745	—	0.996	P00745 →
P25155	—	0.996	P25155 →
Q58L95	—	0.996	Q58L95 →
P16293	—	0.996	P16293 →
P29598	—	0.996	P29598 →
P16294	—	0.996	P16294 →
F7	Coagulation factor VII	0.995	landscape →
Q5E9Z2	—	0.995	Q5E9Z2 →
P83370	—	0.995	P83370 →
Q6SA95	—	0.995	Q6SA95 →
B5G6G5	—	0.995	B5G6G5 →
Q8K3U6	—	0.994	Q8K3U6 →
P19540	—	0.994	P19540 →